摘要
肿瘤相关贫血为肿瘤患者常见的不良反应,其发生率与肿瘤类型、治疗方案和周期疗程等均有关,其发病机制尚未明确。肿瘤相关贫血有可能导致化疗药物剂量降低、化疗时间延迟、需要输注红细胞等,从而增加患者的治疗费用、降低化疗效果和患者的生存质量、缩短生存时间。肿瘤相关贫血的主要治疗包括输注红细胞、促红细胞生成治疗和补充铁剂等。基于文献及临床研究的发展,中国抗癌协会肿瘤临床化疗专业委员会和肿瘤支持治疗专业委员会组织专家制定了《中国肿瘤相关贫血诊治专家共识(2023版)》,相较于《中国肿瘤化疗相关贫血诊治专家共识(2019年版)》,2023版共识采用了新的循证医学证据、纳入了中医相关内容,旨在为肿瘤相关贫血患者提供更为合理的诊疗方案,从而帮助患者改善肿瘤相关贫血,提高生存质量。
Cancer related anemia(CRA)is a common side effect in patients with tumors,the incidence of which is related to tumor type,treatment regimen,the duration of chemotherapy,etc.The pathogenesis of CRA has not been fully defined.CRA may lead to chemotherapy dose reduction or may even delay chemotherapy.Patients with CRA require red blood cell transfusion,thus increasing the treatment cost,reducing the efficiency of chemotherapy and the patient′s quality of life,and shortening the survival time.The main treatments of CRA include red blood cell transfusion,iron supplements,erythropoietin,and so on.Based on recent literature and clinical studies,the expert committee of the China Anti-Cancer Association drew up the consensus on the diagnosis and treatment of anemia related to tumor in China(2023 edition).The 2023 consensus incorporates the latest evidence-based medicine evidence and Traditional Chinese Medicine related content and aims to provide more reliable diagnosis and treatment plans for Chinese oncologists to help improve CRA and the quality of life in patients with cancer.
作者
中国抗癌协会肿瘤临床化疗专业委员会
中国抗癌协会肿瘤支持治疗专业委员会
冯继锋
沈波
The Society of Chemotherapy,Chinese Anti-Cancer Association;Committee of Neoplastic Supportive-Care,China Anti-Cancer Association;Feng Jifeng;Shen bo(不详;Department of Medical Oncology,Jiangsu Cancer Hospital,the Affiliated Cancer Hospital of Nanjing Medical University,Nanjing 210009,China;Department of Day Treatment Center,Jiangsu Cancer Hospital,the Afiliated Cancer Hospital of Nanjing MedicalUniversity,Nanjing 210009)
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2023年第12期1032-1040,共9页
Chinese Journal of Oncology
关键词
恶性肿瘤
肿瘤相关贫血
铁剂
促红细胞生成治疗
专家共识
Malignant tumor
Cancer related anemia
Iron supplements
Erythropoiesis therapy
Expert consensus
